Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kazuo Noguchi

Showing results (21-30 of 40) with videos related to

Pageof 4
Sort By:
Investigational New Drugs|March 23, 2016
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumorsToshio Shimizu, Takashi Seto, Fumihiko Hirai, et al.
Cancer Science|May 23, 2025
KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural MesotheliomaTakashi Kijima, Terufumi Kato, Yasushi Goto, et al.
Cancer Chemotherapy and Pharmacology|December 7, 2011
Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumorsYoshitaka Seki, Noboru Yamamoto, Yosuke Tamura, et al.
Cancer Science|May 26, 2021
Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan StudyHidehito Horinouchi, Naoyuki Nogami, Hideo Saka, et al.
Investigational New Drugs|March 26, 2024
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancerNoboru Yamamoto, Miyako Satouchi, Toshihiko Doi, et al.
Life Sciences|September 14, 2007
NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication modelNorihisa Ishiwata, Kazuo Noguchi, Masafumi Kawanishi, et al.
Cancer Chemotherapy and Pharmacology|March 12, 2017
Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)Naoya Yamazaki, Tatsuya Takenouchi, Manabu Fujimoto, et al.
The Journal of Dermatology|March 26, 2024
Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanomaKenji Yokota, Tatsuya Takenouchi, Yasuhiro Fujisawa, et al.
Cancer Science|January 9, 2019
KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancerMakoto Nishio, Toshiaki Takahashi, Hiroshige Yoshioka, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studiesKaname Nosaki, Hideo Saka, Yukio Hosomi, et al.
Pageof 4

Showing results (21-30 of 40) with videos related to

Sort By:
Pageof 4
Investigational New Drugs|March 23, 2016
Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumorsToshio Shimizu, Takashi Seto, Fumihiko Hirai, et al.
Cancer Science|May 23, 2025
KEYNOTE-A17: First-Line Pembrolizumab Plus Cisplatin-Pemetrexed in Japanese Participants With Advanced Pleural MesotheliomaTakashi Kijima, Terufumi Kato, Yasushi Goto, et al.
Cancer Chemotherapy and Pharmacology|December 7, 2011
Phase I study for ridaforolimus, an oral mTOR inhibitor, in Japanese patients with advanced solid tumorsYoshitaka Seki, Noboru Yamamoto, Yosuke Tamura, et al.
Cancer Science|May 26, 2021
Pembrolizumab plus pemetrexed-platinum for metastatic nonsquamous non-small-cell lung cancer: KEYNOTE-189 Japan StudyHidehito Horinouchi, Naoyuki Nogami, Hideo Saka, et al.
Investigational New Drugs|March 26, 2024
KEYNOTE-434 part B: A phase 1 study evaluating the combination of epacadostat, pembrolizumab, and chemotherapy in Japanese patients with previously untreated advanced non-small-cell lung cancerNoboru Yamamoto, Miyako Satouchi, Toshihiko Doi, et al.
Life Sciences|September 14, 2007
NT-702 (parogrelil hydrochloride, NM-702), a novel and potent phosphodiesterase inhibitor, improves reduced walking distance and lowered hindlimb plantar surface temperature in a rat experimental intermittent claudication modelNorihisa Ishiwata, Kazuo Noguchi, Masafumi Kawanishi, et al.
Cancer Chemotherapy and Pharmacology|March 12, 2017
Phase 1b study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced melanoma (KEYNOTE-041)Naoya Yamazaki, Tatsuya Takenouchi, Manabu Fujimoto, et al.
The Journal of Dermatology|March 26, 2024
Long-term follow-up results from KEYNOTE-041: Phase 1b study of pembrolizumab in Japanese patients with advanced melanomaKenji Yokota, Tatsuya Takenouchi, Yasuhiro Fujisawa, et al.
Cancer Science|January 9, 2019
KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancerMakoto Nishio, Toshiaki Takahashi, Hiroshige Yoshioka, et al.
Lung Cancer (Amsterdam, Netherlands)|August 27, 2019
Safety and efficacy of pembrolizumab monotherapy in elderly patients with PD-L1-positive advanced non-small-cell lung cancer: Pooled analysis from the KEYNOTE-010, KEYNOTE-024, and KEYNOTE-042 studiesKaname Nosaki, Hideo Saka, Yukio Hosomi, et al.
Pageof 4